Compare SHASUN PHARMA with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA NATCO PHARMA SHASUN PHARMA/
NATCO PHARMA
 
P/E (TTM) x 123.9 15.5 797.5% View Chart
P/BV x 8.5 3.1 279.7% View Chart
Dividend Yield % 0.2 1.5 16.0%  

Financials

 SHASUN PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
NATCO PHARMA
Mar-18
SHASUN PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs941,080 8.7%   
Low Rs46671 6.8%   
Sales per share (Unadj.) Rs214.2592.1 36.2%  
Earnings per share (Unadj.) Rs5.3188.4 2.8%  
Cash flow per share (Unadj.) Rs15.8206.3 7.7%  
Dividends per share (Unadj.) Rs1.008.25 12.1%  
Dividend yield (eoy) %1.40.9 151.8%  
Book value per share (Unadj.) Rs53.3833.6 6.4%  
Shares outstanding (eoy) m56.6236.90 153.4%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.31.5 22.1%   
Avg P/E ratio x13.14.6 281.9%  
P/CF ratio (eoy) x4.44.2 104.1%  
Price / Book Value ratio x1.31.1 124.8%  
Dividend payout %18.74.4 428.0%   
Avg Mkt Cap Rs m3,95832,311 12.2%   
No. of employees `000NA4.8 0.0%   
Total wages/salary Rs m2,1643,256 66.4%   
Avg. sales/employee Rs ThNM4,522.5-  
Avg. wages/employee Rs ThNM674.0-  
Avg. net profit/employee Rs ThNM1,439.0-  
INCOME DATA
Net Sales Rs m12,12721,848 55.5%  
Other income Rs m229404 56.8%   
Total revenues Rs m12,35622,252 55.5%   
Gross profit Rs m1,0099,284 10.9%  
Depreciation Rs m594662 89.7%   
Interest Rs m415154 269.5%   
Profit before tax Rs m2308,872 2.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-731,920 -3.8%   
Profit after tax Rs m3026,952 4.3%  
Gross profit margin %8.342.5 19.6%  
Effective tax rate %-31.721.6 -146.3%   
Net profit margin %2.531.8 7.8%  
BALANCE SHEET DATA
Current assets Rs m6,88421,307 32.3%   
Current liabilities Rs m8,4565,920 142.8%   
Net working cap to sales %-13.070.4 -18.4%  
Current ratio x0.83.6 22.6%  
Inventory Days Days6273 84.1%  
Debtors Days Days108107 101.0%  
Net fixed assets Rs m4,97014,986 33.2%   
Share capital Rs m113369 30.7%   
"Free" reserves Rs m2,87530,353 9.5%   
Net worth Rs m3,02030,760 9.8%   
Long term debt Rs m1,8170-   
Total assets Rs m13,34737,151 35.9%  
Interest coverage x1.658.6 2.7%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.90.6 154.5%   
Return on assets %5.419.1 28.1%  
Return on equity %10.022.6 44.3%  
Return on capital %13.329.3 45.4%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84310,322 56.6%   
Fx outflow Rs m2,1732,978 73.0%   
Net fx Rs m3,6697,343 50.0%   
CASH FLOW
From Operations Rs m3984,636 8.6%  
From Investments Rs m-1,635-11,155 14.7%  
From Financial Activity Rs m1,3096,509 20.1%  
Net Cashflow Rs m71-18 -395.6%  

Share Holding

Indian Promoters % 39.2 52.0 75.3%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 3.6 7.8 45.9%  
FIIs % 17.6 16.6 105.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 26.0 152.3%  
Shareholders   20,750 25,395 81.7%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   JUBILANT LIFE SCIENCES  PLETHICO PHARMA  WOCKHARDT  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS